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Blister development in bullous pemphigoid (BP) results from destruction of hemidesmosomes and basement membrane compo-
nents within the dermoepidermal junction by autoantibodies. Adhesion molecules can take part in pathogenesis of this disease.
The aim of the study was to determine the localization and expression of L- and E-selectins and β1, β3, and β4 integrins by im-
munohistochemistry in skin lesions of 21 patients with BP, compared with 10 healthy subjects. Expression of L and E selectins and
β1, β3 integrins was detected mainly in basal keratinocytes and in inﬂammatory inﬁltrates in the dermis, expression of β4 integrin
was irregular and was detected mainly in dermal part of the blister, while in the control group only weak and single expression of
the examined molecules was detected in basal keratinocytes and endothelium cells. The obtained results reveal the important role
of selected selectins and integrins in development of skin lesions in BP.
Copyright © 2007 Agnieszka ˙ Zebrowska et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Development of skin lesions in the course of bullous pem-
phigoid (BP) results from destruction of basement mem-
brane components. Complex structure of this membrane
is responsible for maintaining the integrity of dermo-
epidermal junction. Two glycoproteins of molecular mass
230 kD (BPAG1) and 180 kD (BPAG2) are the autoantigens
in bullous pemphigoid. Structural studies revealed that ex-
tracellularfragmentofBPAG2withCOOH-terminalcollage-
nous domain connects the basement membrane with epider-
mal hemidesmosomes. NC16a fragment of BPAG2, located
within its extracellular fragment, is thought to be the most
immunogenic part of the antigen. Binding of autoantibodies
directedagainsttheseautoantigens,localizedinthebasement
membraneoftheepidermis,activatesaseriesofimmunolog-
ical and enzymatic phenomena [1, 2].
Inﬂammatory inﬁltrates in the dermis, formed by neu-
trophils and eosinophils, and bound in vivo IgG and C3 de-
posits along the basement membrane of the epidermis are
observed. Ultrastructural studies conﬁrmed also the pres-
enceofintensiveinﬂammatoryinﬁltrateatdermo-epidermal
junction, as well as destruction of hemidesmosomes and
components of extracellular matrix [3]. Formation of the
inﬁltrates is preceded by early accumulation of leukocytes,
depending on activity of adhesion molecules, especially se-
lectins and integrins. Schmidt et al. [4] observed that bind-
ing of autoantibodies with BPAG2 leads to activation of ker-
atinocytes, which release interleukin 6 and interleukin 8, as
well as activation of C5 component of the complement. Mast
cells and neutrophils activated by the same immunological
reaction migrate through walls of blood vessels with help of
EandLselectins andsecretespeciﬁcproteasesthatcandigest
a series of basement membrane proteins. Matrix metallopro-
teinases, released by inﬂammatory cells and keratinocytes,
are ﬁnally responsible for blister formation [5, 6]. Migration
of immunocompetent cells from blood vessels into foci of
inﬂammation has several phases. In each stage of this pro-
cess diﬀerent families of adhesion molecules are involved, re-
sponsible for rolling, adhesion, activation, binding, and dia-
pedesis of leukocytes [7].
During the ﬁrst stage (leukocyte rolling), binding of E
and L selectins with oligosaccharide ligands results in the so-
calledmarginalizationofthecells,forexample,directcontact
of leukocytes with the endothelium. Second stage, leukocyte
activation, is characterized by increased aﬃnity of integrin
receptors on rolling leukocytes. Cytokines produced locally
infociofinﬂammationcausehaltingofrollingcellsandtheir2 Mediators of Inﬂammation
pushing through the epithelium [6–8]. Subfamilies of inte-
grins, for example, β1a n dβ3, are involved in the third stage,
termed strong adhesion. During the fourth stage diapedesis
and migration in tissues can be observed [6, 7, 9].
Adhesion molecules have an important role during fur-
ther extravascular stages of migration. They are transmem-
brane glycoproteins composed of extracellular, intramem-
brane, and cytoplasmatic functional domains [7]. The β4 in-
tegrin is additionally involved in connecting the ﬁlaments of
thecelltothebasementmembraneandforminghemidesmo-
somes. Destruction of these hemidesmosomes is an essential
process in development of skin lesions in BP [3].
Continued research concerning modulation of activity of
selected selectins and integrins that are involved in processes
taking place within the skin may contribute to development
of new therapeutic methods for various dermatoses, espe-
cially bullous skin diseases.
There are few literature data concerning variations of se-
lected adhesion molecules serum levels or examinations on
animal models in bullous pemphigoid. The aim of the study
was to determine the localization and expression of E and
L selectins and β1, β3, and β4 integrins in lesional skin of
patients with bullous pemphigoid and in skin of healthy per-
sons.
2. MATERIAL AND METHODS
The study included 21 patients with BP (15 women and 6
men, aged between 58 and 84 years, mean age 68.5) in ac-
tive stage of the disease. All patients had skin lesions-blisters,
vesicles, papules, or erythema. Control group consisted of
10 healthy persons (5 women and 5 men, ages between 19
and 49 years, mean age 42). The study was approved by local
ethics committee of Medical University of Lodz.
Diagnosis of bullous pemphigoid was based on clinical
picture as well as histological and immunological examina-
tions. 11 patients had skin lesions in form of blisters, vesicles,
and itching erythematous papules, the rest of patients pre-
sented with only erythema.
In all patients, direct immunoﬂuorescence test revealed
bound in vivo IgG/C3 linear deposits along basement mem-
brane zone. In salt split test, the deposits were observed in
epidermal part of the blister, or both in epidermal and der-
mal parts. By indirect immunoﬂuorescence test circulating
IgG antibodies were found in 17 out of 21 patients, while
ELISA test (MBL, Nagoya, Japan) showed the presence of
anti-NC16a autoantibodies in 19 cases. In histological ex-
amination, features consistent with diagnosis of BP were ob-
served, such as neutrophilic, eosinophilic, and lymphocytic
inﬁltrates, and in 11 cases—subepidermal blisters.
Immunohistochemistry was used to evaluate the expres-
sionsofstudiedadhesins.Biopsiesforimmunohistochemical
examinationwereobtainedfromlesionalskininpatientsand
from the nape region in healthy controls.
Paraﬃn-embedded sections were used for routine H + E
staining and for immunohistochemistry in DAKO EnVision
detection system using immunoperoxidase method. The fol-
lowing primary monoclonal antibodies were used: CD29
(β1 family), CD61 (GPIII) (β3 family), CD104 (β4f a m i l y ) ,
CD62E (E-selectin), and CD62L (L-selectin), (Novocastra,
United Kingdom).
For immunohistochemistry the paraﬃn-embedded sec-
tions were placed on adhesive plates and dried at 56◦Cf o r2 4
hours, later deparaﬃnated in a series of xylens and alcohols
with decreasing concentrations (96%, 80%, 70%, 60%). Ac-
tivity of endogenous peroxidase was then inhibited with 3%
hydrogen peroxide solution in methanol for 5 minutes.
In order to retrieve the antigenicity of tissues and allow
them to react with antibodies, the following procedures were
usedforeachofthetestedantibodies:forCD62Ethesections
were heated in 0.001M versenian buﬀer (EDTA) of 8.0 pH
in water bath at 95◦ for 30 minutes; for CD62L the sections
were boiled in 0.001M versenian buﬀer (EDTA) of 8.0 pH in
microwave oven at 700W for 15 minutes; for CD29 the sec-
tions were heated 6 times in 0.01M citrate buﬀer of 6.0 pH
in microwave oven at the following power levels: 150W (5
minutes), 350W (5 minutes), 450W (5 minutes), and 650W
(6 minutes); for CD61 and CD104 the sections were heated
in DAKO target retrieval solution in water bath at 95◦ for 30
minutes. Cooled sections were then rinsed in 0.05M TRIS
buﬀer (TBS) at 7.6 pH for 30 minutes and incubated for 60
minutesatroomtemperatureindampchamberwith,respec-
tively, diluted antibodies CD62E (E-selectin) 1 : 50, CD62L
(L-selectin) 1 : 50, CD29 1 : 40, CD61 (GPIII) 1 : 25, CD104
1 : 50. After incubation the sections were rinsed twice in TBS
buﬀer and DAKO EnVision double-step visualization system
was next applied in order to visualize the antigen-antibody
reaction.
The following semiquantitative scale was applied for
evaluation of the intensity of immunohistochemical reaction
ofCD29,CD61,CD104,CD62E,andCD62Linskinbiopsies:
−: no reaction, +: weak intensity in most cells, 2+: moderate
intensity, 3+: strong intensity.
Expression of selectins and integrins was assessed by two
independent pathologists using Olympus BX 41 microscope
(Japan). Whole slideswith allﬁelds of microscopic view were
investigated.
3. RESULTS
Results of semiquantitative evaluation of expression of stud-
ied integrins and selectins in immunohistochemical exami-
nation are presented in Table 1.
3.1. Integrinβ1(CD29)
Immunoexpression of integrin β1 (CD29) was detected in all
basal keratinocytes. In skin samples from patients with BP,
mean intensity of immunoexpression was weak (14/21) (see
Figure 1). Moderate expression of CD29 was observed in 4 of
21patients.Inskinsamplesobtainedfromhealthyvolunteers
expression was very weak and detected only in single cells
(see Figure 2).
3.2. Integrinβ3(CD61)
Reaction with CD61 antibody was positive in skin samples
from patients and was localized in basal keratinocytes andAgnieszka ˙ Zebrowska et al. 3
Table 1: Mean immunoexpression of CD29, CD61, CD104, CD62E, and CD62L in BP and control group.
Adhesion molecule CD29 (integrin β1) CD61 (integrin β3) CD104 (integrin β4) CD62E (E-selectin) CD62L (L-selectin)
Expression/patients Expression/patients Expression/patients Expression/patients Expression/patients
Pemphigoid
+1 4 /21 +1 4 /21 +1 4 /21 +1 5 /21 +1 5 /21
2+ 4/21 2+ 2/21 2+ 4/21 2+ 5/21 2+ 2/21
− 3/21 − 5/21 − 3/21 3+ 1/21 − 4/21
Control group +3 /10 +0 /10 +8 /10 +5 /10 +4 /10
− 7/10 − 10/10 − 2/10 − 5/10 − 6/10
Figure 1: Skin lesions in BP, immunohistochemistry. Moderate ex-
pression of β1 integrin in basal keratinocytes and weak in the whole
epidermis and blister ﬂuid (original magniﬁcation x100).
Figure 2: Healthy skin, immunohistochemistry. Signal for β1 inte-
grin in single keratinocyte (original magniﬁcation x400).
focally also in other layers of the epidermis (see Figure 3).
Mean intensity of immunoexpression of CD61 was weak
(14/21). In control skin samples, immunoexpression of β3
integrins (CD61) was not observed.
3.3. Integrinβ4(CD104)
Immunoexpression of integrin β4 (CD104) was detected in
hemidesmosomes in BP samples as well as in control biop-
sies.Inlesionalskinbiopsiesfrompatients,expressionwasir-
regularly scattered along basement membrane (see Figure 4),
while in healthy skin it was regular and linear (see Figure 5).
Mean intensity of CD104 expression in pemphigoid was
weak (14/21).
Figure 3: Skin lesions in BP, immunohistochemistry. Moderate ex-
pression of β3 integrin in basal keratinocytes and weak in the whole
stroma (original magniﬁcation x100).
Figure 4: Skin lesions in BP, immunohistochemistry. Moderate ex-
pression of β4 integrin in the dermal part of blister and in blister
ﬂuid (original magniﬁcation x100).
3.4. E-selectin(CD62E)
Immunoexpression of E-selectin in skin samples from BP
patients was detected on endothelial cells and neutrophils
(see Figure 6). Mean intensity of CD62E immunoexpression
in patients was weak (17/21). In biopsies from healthy skin,
only single endothelial cells showed very weak expression of
CD62E.
3.5. L-selectin(CD62L)
Immunoexpression of L-selectin was detected on limpho-
cytes, macrophages, and neutrophils (see Figure 7). Mean
intensity of expression of CD62L in pemphigoid was weak.4 Mediators of Inﬂammation
Figure 5: Healthy skin, immunohistochemistry. Signal for β4 inte-
grin in single basal keratinocyte (original magniﬁcation x100).
Figure 6: Skin lesions in BP, immunohistochemistry. Moderate ex-
pression of L-selectin on leucocytes (original magniﬁcation x100).
In biopsies from healthy skin very weak expression was ob-
served only on single endothelial cells.
4. DISCUSSION
Pemphigoid is a subepidermal bullous dermatosis in which
pathological processes result in disconnection between basal
layer of the epidermis and the dermis, causing formation
of tense blisters. It was proved that administration of rab-
bit anti-mBP180 antibodies to newborn mice causes pro-
duction of pathological antibodies, accumulation of leuko-
cytes, and formation of complement deposits along base-
mentmembranethatresultsindevelopmentofblisters[4,9].
Scare literature data revealed the role of certain adhesive
molecules in the pathogenesis of BP. Recent studies estab-
lishedbiochemicalpropertiesofmetalloproteinasesandtheir
tissue inhibitors and their high aﬃnity to components of the
basement membrane zone. These enzymes are produced by
eosinophils and neutrophils attracted to the basement mem-
brane by selectins and integrins.
Integrins belong to particles that are very important for
maintaining the dermo-epidermal junction as well as cell-
to-cell connections. Lack of β1 integrin during fetal devel-
opment in mice is a lethal mutation [8, 10, 11]. Genetic or
autoimmune dysfunction of α6β4 integrin causes bullous le-
sions on the skin and mucous membranes in the course of
Figure 7: Skin lesions in BP, immunohistochemistry. Strong ex-
pression of E-selectin on endothelial cells (original magniﬁcation
x100).
such diseases as junctional type of bullous epidermolysis or
cicatricans pemphigoid. Expression of various integrins on
keratinocytes,ﬁroblasts,endothelialcells,andmigratingcells
is also necessary for normal healing processes and for occur-
rence of the apoptosis phenomenon [12, 13]. Increased ex-
pression of integrins is associated with promotion of cell mi-
gration, production of metalloproteinases, and angiogenesis
[14, 15].
Activation of various signal transduction pathways de-
pendsonthefamilyofintegrins,typeofassociatedECMpro-
tein, and stimulating factors. Integrin stimulating factors are
cytokines, growth factors, chemokines, and other adhesion
molecules,includingcytokinesthemselves[14–16].Somelit-
erature date conﬁrm the role of these cytokines, chemokines,
and ECM enzymes in pathogenesis of BP [4, 5].
Integrins are heterodimers build from α and β chains
connected noncovalently that pass through the cytoplas-
matic membrane, joining extra and intracellular environ-
ments [7, 17, 18]. Linkage of an integrin with ligand ini-
tiates signaling cascade that modulates cell behavior and
gene transcription [19]. Integrins are main cellular recep-
tors for binding with extracellular matrix components (e.g.,
plectin, ﬁbronectin, vitronectin, collagen) through special
short protein fragments and are involved in intercellular ad-
hesion in epidermis [20, 21]. β1 subfamily integrins are in-
volved mainly in the interactions between cells and connec-
tive tissue macromolecules (e.g., ﬁbronectin, laminin, colla-
gen); β2 are associated with cell-to-cell interactions, while
β3 play a role in connections with ligands such as ﬁbrino-
gen, vitronectin, thrombospondin, and von Willebrand fac-
tor [7,18].β1integrinsubunitwasdetectedinupperandlat-
eral parts of cellular membrane of basal keratinocytes, while
it was very seldom observed in its lower parts. This obser-
vation may suggest that this molecule is involved mainly
in maintaining the intercellular connection [20]. Molecules
that belong to β1 subfamily of integrins may become ex-
p r e s s e da sl a t ea s2t o7w e e k sa f t e rl y m p h o c y t es t i m u l a -
tion.
In our study, expression of β1 integrin in all basal ker-
atinocytesinlesionalskinbiopsiesfrompemphigoidpatients
wasobserved,incomparisonwithveryweaksignalfromonly
single cells in the control group, revealing the important roleAgnieszka ˙ Zebrowska et al. 5
of lymphocyte stimulation and production of cytokines in
this disease. The expression in all basal keraqtinocytes is an
answer for signiﬁcantly lymphocyte inﬁltration.
β3 integrin is a transmembrane glycoprotein, expressed
mainly on platelets and megakaryocytes. It binds with CD51
molecule, creating a receptor for vitronectin, and thus be-
comes expressed in the cells of many tissues. Moreno et
al. [11] used monoclonal antibodies against this integrin, re-
vealing its presence in epithelium of mouse’s kidneys and
testicles. Structural and functional analysis of β3 integrin
fragments showed its strong adhesive potential and ability
to inﬂuence the function of ﬁbrinogen, explaining the ex-
pression of this integrin during the inﬂammatory process as
well as its presence on other cells, including epithelial cells
[4, 22].
In our study, expression of this integrin was observed on
single epidermal cells. Positive signal was detected in lesional
skin biopsies, comprising basal keratinocytes or focally cells
from other layers of the epidermis. It seems that the inﬂam-
matory process and destruction of dermo-epidermal junc-
tion may be induced by expression of β3 on keratinocytes,
but such phenomenon should be conﬁrmed by other diag-
nostic methods.
Hemidesmosomes are multiprotein complexes respon-
sible for adhesion of epithelial cells to extracellular ma-
trix. They are composed, among others, from α6β4 integrin,
BP180, CD151, and plectin [21, 23]. Results of in vitro stud-
ies reveal that α6β4 integrin plays a key role in development
of hemidesmosomes. This integrin is involved in connecting
the intermediate ﬁlaments of a cell to the basement mem-
brane and antibodies directed against this molecule inhibit
both creation of hemidesmosomes and function of existing
structures [23, 24]. Pemphigoid antigens BP180 and BP230
are linked not only to each other, but BP230 and β4 bind
alsowithBP180[21].InteractionofBP180andα6β4integrin
subunit is necessary for stabilization of hemidesmosomes
structure [25, 26]. It was demonstrated that sole interaction
between BP180 and plectin is not suﬃcient for hemidesmo-
some formation when lacking α6β4 integrin [21].
Complex interactions at the dermo-epidermal junction
are also conﬁrmed by other in vitro studies [27]. Studies in
patients with ophthalmologic type of cicatrisans pemhigoid
underline the role of antibodies directed against β4 integrin.
Serumformpatientswithcicatrisanspemphigoidrecognized
a protein of molecular mass 205kDa, for example, that of
β4 integrin. Such protein was not recognized by sera from
patients with bullous pemphigoid or pemhigus vulgaris [28–
30].
Bhol et al. [31] revealed that serum from pemphigoid pa-
tients who had lesions on oral mucosa selectively binds hu-
man α6β4 integrin. In 48-hour culture with human oral mu-
cosa obtained from the cheeks, this serum caused separation
of epidermis from the basement membrane. Antibodies may
bind intracellulary with speciﬁc domains leading in conse-
quence to development of skin lesions [14, 31].
Leverkus et al. [27] using immunoblot method revealed
decrease of antibodies’ reactivity against BP180 and β4
integrin that correlated with decreased activity of ocular
pemphigoid resulting from introduced treatment. Rashid
et al. [32] examined sera from 20 patients with mucous
membrane pemphigoid in active stage of the disease and
demonstrated that all studies sera bound with α6 integrin
subunit in immunoprecipitation and immunoblot methods.
F o c a ll o s so fe x p r e s s i o no fα6β4 integrin is associated with
loss of adhesion to the basement membrane.
Kurpakus et al. [33] examined the role of α6β4i nh e m i -
desmosome formation on an in vitro model of wound heal-
ing and revealed that antibodies against β4 subunit did
not disturb migration of epithelial cells but they initiated
disruption of formerly assemblied hemidesmosomes. New
hemidesmoses were also no longer formed and antibodies
againstα6β4integrincompletelyisolatedepithelialcellsfrom
the area of healing.
Our study revealed weak but linear and regular expres-
sion of β4 integrin in skin biopsies from healthy persons.
Such expression proves that the presence of this molecule
is constitutive in epidermal anchoring structures. However,
in the course of immunologic delamination of the epider-
mis in BP, mediated by antibodies directed against base-
ment membrane components and caused by a cascade of cy-
tokine and enzymatic reactions, this expression was signiﬁ-
cantlychanged.Irregularandfocalexpressionofthisintegrin
within the inﬂammatory inﬁltrates and blisters may reﬂect
the destruction of the dermo-epidermal junction.
Selectins belong to the ﬁrst family of adhesion molecules
that initiate diapedesis, for example, rolling of leukocytes.
This family encompasses three transporting glycoproteins
with similar structure: leukocyte (L), platelet (P), and en-
dothelial (E) selectin. Selectins are involved in leukocyte re-
cruitment to the inﬂammatory foci and in the initial stages
of inﬂammation play a role in rolling of leukocytes on the
endothelium of blood vessels [18].
E-selectin is present in the stimulated endothelial cells.
Production of this molecule is induced by a bacterial en-
dotoxin, cytokines, thrombin, or tumor necrosis factor α
(TNFα). Expression of E-selectin can be observed only in
the foci of inﬂammation [18]. In our studies, expression of
this selectin was observed in walls of blood vessels, slightly
weaker in neutrophils. It conﬁrms the role of the E-selectin
in inﬂammatory process and development of pathological
changes in pemphigoid.
D’Auria et al. [34] in a preliminary study examined
serumconcentrationofsolubleE-selectininpemphigoidand
pemphigus vulgaris patients and revealed its signiﬁcant in-
crease in patients in comparison with the control group, as
well as signiﬁcant correlation with a number of skin lesions.
In course of therapy, both severity of skin lesions and con-
centration of studied selectin decreased in parallel, which
may prove the usefulness of E-selectin as a treatment eﬃcacy
marker.
L-selectin is constitutively present on leukocyte surface
and disappears after their stimulation. It has an important
role in neutrophil recruitment to foci of inﬂammation and
lymphocyte adhesion to endothelial cells of blood vessels in
peripheral lymph nodes. The soluble form of this molecule
is probably involved in regulation of adhesion processes6 Mediators of Inﬂammation
[3, 18, 35]. Based on the fact that the inﬂammatory process
is associated with leukocyte stimulation, lower expression of
L-selectin in patients in comparison with the control group
was expected in our study. Immunoexpression of L-selectin
was however observed on lymphocytes, macrophages, and
neutrophils. It may prove that not all inﬂammatory cells are
simultaneously stimulated and some of them can still retain
the L-selectin on the surface before its desquamation.
Recent literature data as well as results of our studies
conﬁrm the role of selectins and integrins in pathogenesis
of pemphigoid. The elucidation of the role of inﬂammatory
cells, their soluble mediators, adhesion molecules, and sig-
nal transduction pathways in the pathogenesis of the bul-
lous diseases may be helpful in the development of new tar-
geted therapies. Extensive research has focused on modulat-
ing activity of adhesive molecules. Among the new therapeu-
ticmodalities,humanizedmonoclonalantibodiesagainstad-
hesion molecules are in early phase of clinical trials [36].
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